On December 18, 2024, Deepa Prasad, a Director at Design Therapeutics Inc (DSGN, Financial), sold 3,806 shares of the company. Following this transaction, the insider now owns 20,000 shares of the company. The details of this transaction can be found in the SEC Filing.
Design Therapeutics Inc (DSGN) is a biotechnology company focused on developing novel small molecule therapies for serious degenerative diseases caused by inherited nucleotide repeat expansions. The company's approach aims to address the underlying cause of these diseases by targeting the genetic mutations responsible for them.
Over the past year, Deepa Prasad has sold a total of 3,806 shares and has not purchased any shares. The insider transaction history for Design Therapeutics Inc indicates that there have been two insider buys and two insider sells over the same timeframe.
On the day of the recent sell, shares of Design Therapeutics Inc were trading at $6.27 each, giving the stock a market cap of $339.160 million. Investors may consider various valuation metrics such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when evaluating the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
